FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Williams Gregory C.</u>				2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ ELOX ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner							
	`	MACEUTICAL	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/30/2021								helow	Officer (give title Other (specify below) below)  CHIEF EXECUTIVE OFFICER				
(Street) WALTH			02451 (Zip)		-   4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deriv	vative	e Se	curiti	ies Ac	auired.	Dis	posed o	of. or Be	neficial	lly Owne	d d				
1. Title of Security (Instr. 3)		2. Trans	nsaction 2 h/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		ed (A) or	5. Amor Securit Benefic Owned	unt of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	rect direct E	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)		1	Instr. 4)	
Common Stock 01/30/			0/2021	2021		М		1,875	5 A	\$0(1	) 10	10,632							
Common Stock 01/30/			0/2021	2021		F		643	D	\$3.44	(1) 9	9,989							
		Т										, or Ben ble secu		/ Owned					
Derivative Conversion Date Execurity or Exercise (Month/Day/Year) if an			3A. Deem Execution if any (Month/Da	n Date, Tran Cod		ansaction of Deriv Secu Acqu (A) on Dispo		oosed D) tr. 3, 4	6. Date Exercis. Expiration Date (Month/Day/Yea		:	Amount of		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	Ow Fo Dir or (I)	mership rm: ect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Restricted Stock	(1)(2)	01/30/2021			M			1,875	(1)		(1)	Common Stock	1,875	\$0 <sup>(3)</sup>	15,000 <sup>0</sup>	(4)	D		

## **Explanation of Responses:**

- 1. The restricted stock units issued to the reporting person on January 30, 2019 have partially vested and settled for shares of the Issuer's common stock.
- 2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 3. The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan.
- 4. The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances.

/s/ Neil S. Belloff, Attorney-in-Fact 02/02/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.